FDA Approves STAMP Inhibitor for Chronic Myeloid Leukemia

(MedPage Today) -- The FDA granted accelerated approval to the STAMP inhibitor asciminib (Scemblix) for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase for patients previously treated with two or...